Medical Researchers Have Discovered Possible New Mesothelioma Blood Biomarker

Team of medical scientists just identified blood biomarker for asbestos mesothelioma that may possibly help in improving the identifying diagnosis and prognosis accuracy process and personalization of treatment.

Medical Researchers were able to identify the chemical activin A, protein complex that is found in the blood, as potential target in identifying therapies in the future.

mesothelioma lawyer directory

It has been stated by Dr. Balazs Hegedus, from the medical university of vienna in austria that “blood derived biomarkers are important because they can be noninvasive measured, even at multiple stages. They can help make the best personalized therapeutic decisions.

It is also noted that Hegedus, cancer specialist from Hungary, Switzerland and Australia also participated  in the cancer study that was published in the European journal of Cancer Issue.

In the study the researchers measured the activin A levels of approxiately 129 patients in several locations, where 16 patients with nonmalignant pleural diseases and about 45 health subjects for an in-depth analysis.

It was discovered that the medical researchers identified higher activin A levels in medical subjects
that have been identified with asbestos mesothelioma patients and noticed the increased tumer volume that is directly related with higher levels of circulation protein.

It was also identified that these patients who have been identified with lower levels of activin A at
diagnosis stage are living longer.

Activin A Helps with Histology

Medical patients that have been identified with nonmalignant diseases who only had a slight uptick
in activin A, which is also known to help improve and determine histological classification of asbestos-mesothelioma.

Medical patients who have been identified with sarcomatoid and biphasic mesothelioma, which are the two strongest types of treat, had a slightly highter level of activin A than the epithelioid types.

Activin A is stated to be the first asbestos-mesothelioma biomarker to help better identify histological
differences. Some other biomarkers, such as fibulin-3, are unable to make the distinction.

Asbestos-Mesothelioma is a rare form of an aggressive cancer that is induced by breathing or taking in asbestos fibers. It is a cancer that is very difficult to diagnose and often times it can grow and metastasize usually before doctors can obtain a positive diagnosis.

To learn more about mesothelioma lawyer who can help assist with learning more about asbestos-mesothelioma please visit